SCHEMBL301185

SCHEMBL301185

CCNc1ncc(C)c(Nc2cccc(S(=O)(=O)N3CCCCC3)c2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
LMNA P02545 3/20 0.52
HTT P42858 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
KDM4E B2RXH2 2/20 0.52
GAA P10253 2/20 0.52
MAPT P10636 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
POLB P06746 1/20 0.52
HPGD P15428 1/20 0.52
RECQL P46063 1/20 0.52
BRD4 O60885 6/20 0.50
JAK3 P52333 5/20 0.50
JAK1 P23458 3/20 0.50
EGFR P00533 3/20 0.50
BTK Q06187 3/20 0.50
JAK2 O60674 3/20 0.50
RET P07949 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10260766 0.99 KDM4E (0.52) ALDH1A1LMNAHTTSMN1; SMN2MEN1
SCHEMBL10267648 0.90 JAK1 (0.53) ALDH1A1POLBBRD4JAK3JAK1
SCHEMBL17915964 0.89 ALDH1A1 (0.54) ALDH1A1LMNAHTTSMN1; SMN2MEN1
SCHEMBL17915905 0.88 KDM4E (0.54) ALDH1A1LMNAHTTSMN1; SMN2MEN1
SCHEMBL270236 0.86 BRD4 (0.54) ALDH1A1LMNAHTTSMN1; SMN2MEN1
SCHEMBL12320856 0.85 ALDH1A1 (0.51) ALDH1A1LMNAHTTSMN1; SMN2MEN1
SCHEMBL12111057 0.85 JAK3 (0.48) ALDH1A1LMNASMN1; SMN2KDM4EHPGD
SCHEMBL24124309 0.85 JAK3 (0.57) ALDH1A1LMNAHTTSMN1; SMN2MEN1
SCHEMBL270240 0.85 BRD4 (0.55) ALDH1A1LMNAHTTSMN1; SMN2MEN1
SCHEMBL10261765 0.83 JAK3 (0.49) BRD4JAK3JAK1EGFRBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951684-B1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES TARGEGEN INC (US) 2016-07-13 EP disclosed
US-8133900-B2 Use of bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2012-03-13 US disclosed
US-20110269721-A1 METHODS OF TREATING THALASSEMIA TARGEGEN, INC. (US) 2011-11-03 US disclosed
US-20090286789-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases TARGEGEN, INC. (US) 2009-11-19 US disclosed
US-7528143-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2009-05-05 US disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286789-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases JAK2, TYK2, LTK ALDH1A1 3662/4885LMNA 4525/4885HTT 2734/4885
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 ALDH1A1 3235/4885LMNA 4817/4885HTT 3657/4885
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 ALDH1A1 3235/4885LMNA 4817/4885HTT 3657/4885
US-20110269721-A1 METHODS OF TREATING THALASSEMIA JAK2, STAT5A, STAT5B ALDH1A1 1825/4885LMNA 2236/4885HTT 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.